Patient-reported outcomes (PRO) from a phase I/II dose-escalation study of fractionated dose 177Lu-PSMA-617 for progressive metastatic castration-resistant prostate cancer (mCRPC).

Panagiotis J. Vlachostergios,Sukanya Goswami,Muhammad Junaid Niaz,Charlene Thomas,Paul J. Christos,Joseph R. Osborne,Shankar Vallabhajosula,Ana M. Molina,Cora N. Sternberg,Sharon Singh,Angela Tan,Amie Patel,David M. Nanus,Neil H. Bander,Scott T. Tagawa

Patient-reported outcomes (PRO) from a phase I/II dose-escalation study of fractionated dose 177Lu-PSMA-617 for progressive metastatic castration-resistant prostate cancer (mCRPC).

2020

Panagiotis J. Vlachostergios
Sukanya Goswami
Muhammad Junaid Niaz
Charlene Thomas
Paul J. Christos
Joseph R. Osborne
Shankar Vallabhajosula
Ana M. Molina
Cora N. Sternberg
Sharon Singh
Angela Tan
Amie Patel
David M. Nanus
Neil H. Bander
Scott T. Tagawa

45Background: We performed the 1st dose-escalation study of PSMA-targeted radionuclide therapy with 177Lu-PSMA-617. Using dose-fractionation, we intended to deliver a dose-intense regimen designed ...

Keywords:

radionuclide therapy
dose escalation
Oncology
Castration
177Lu-PSMA-617
Prostate cancer
Pathology
Regimen
Internal medicine
Medicine
phase i ii
castration resistant

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations